Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (2547)	10/28/1997 11:39:00 PM
From: Oliver & Co	Respond to of 6136

Just in from work. What a day, I told you last night. Buy,Buy, Buy. We treat asymptomatic HIV patients depending on multiple factors. Prior experience, viral load, etc. We use a lot of AZT/3TC, alone or in combo with viramune, or viracept. Also use ddi/PI/NNRTI. But we may use several combos. Ther is no one combo for everyone. Probably the most common is something with Viracept. It is very well tolerated. Rescriptor is a good addition. Salvage therapy with SQV/Norvir and something/s else are also used. I have a couple of people on AZT/DDI/VIRACEPT/RESCRIPTOR OR /CRYXIVAN/ We try to give everyone either AZT or Zerit because of CNS penetration. I will be leaving for the "HIV Speakers Forum", in Phoenix, on thursday. Doug Richman,MD will be the Keynote speaker. The title of his talk will be "Viral Eradication-is the cure at hand?" The schedule also includes: Update on 141 and other second gen PIs. Combination of PIs. Update on 1592, etc, etc. The faculty include Drs Kessler and Schooley. The AGPH meeting is around Nov 16. If we do not talk again. Good luck, and may the good trades be yours. JLL